Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Advancements in biotechnology and immunotherapy
3.2.1.3 Growing demand for personalized medicine
3.2.1.4 Rising geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with cancer vaccine development
3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Preventive vaccine
5.3 Therapeutic vaccine
Chapter 6 Market Estimates and Forecast, By Technology, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Recombinant cancer vaccine
6.3 Whole-cell cancer vaccine
6.4 Viral vector & DNA cancer vaccine
6.5 Antigen/adjuvant cancer vaccine
6.6 Other technologies
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Prostate cancer
7.3 Cervical cancer
7.4 Colorectal cancer
7.5 Lung cancer
7.6 Melanoma
7.7 Other applications
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Cancer treatment centers
8.4 Academic and research institutes
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Ayala Pharmaceuticals
10.2 AstraZeneca PLC
10.3 Amgen Inc.
10.4 Bristol-Myers Squibb Company
10.5 Dynavax Technologies Corporation
10.6 Dendreon Pharmaceuticals LLC
10.7 Ferring Pharmaceuticals
10.8 F. Hoffmann-La Roche Ltd
10.9 GeneReach Biotechnology Corp.
10.10 GSK plc
10.11 EOM Pharmaceutical Holdings, Inc.
10.12 Merck & Co., Inc.
10.13 Moderna, Inc.
10.14 OSG Immunotherapeutics
10.15 Sanofi
